Predictive Gene Editing Using CRISPR and AI: Synergistic Advances in Genomic Therapeutics

Predictive gene editing, which is the integration of CRISPR-based genome engineering with artificial intelligence, is poised to transform genomic medicine by maximizing genome alteration precision, safety, and personalized customization. Here, we merge recent advances in CRISPR toolkit evolution involving Cas9, Cas12, base and prime editors, and RNA-targeting modalities with AI-driven approaches that optimize guide-RNA design, predict off-target impacts, and simulate repair outcomes using deep learning and multimodal data integration. We highlight leading computational platforms in which sequence context, chromatin states, and single-cell information are combined to improve specificity and predict results of editing before experimental proof. Circuits for clinical application already benefiting from such technologies include rectified monogenic disease, designer immunotherapies, and RNA-targeted antiviral therapies. Current obstacles including bias in data; insufficient generalization across contexts; delivery shortcomings; model interpretability; and ethical and regulatory considerations are explored in parallel with experimental proof-of-concept tools (such as GUIDE-seq, Digenome-seq, and others) confirming computational predictions. Future directions for translation likely accelerators include multimodal and interpretable AI for next-generation CRISPR tools; real-time feedback in conjunction with biosensor control; prime/base editing optimizers with contextual awareness; and formidable governance frameworks for equitably implementing next-generation therapies. Predictive gene editing is ready to usher in next-generation precision medicine; its promise will only be fulfilled by concerted advances involving algorithms, experimental proof-of-concept tools, delivery mechanisms, and ethical governance.